<SEC-DOCUMENT>0001193125-25-013864.txt : 20250128
<SEC-HEADER>0001193125-25-013864.hdr.sgml : 20250128
<ACCEPTANCE-DATETIME>20250128073554
ACCESSION NUMBER:		0001193125-25-013864
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250128
DATE AS OF CHANGE:		20250128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RAPT Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001673772
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				473313701
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284388
		FILM NUMBER:		25560949

	BUSINESS ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 489-9000

	MAIL ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLX Bio, Inc.
		DATE OF NAME CHANGE:	20160504
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d885645d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to
Rule 424(b)(3) <BR> Registration No. 333-284388 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g885645g03l00.jpg" ALT="LOGO" STYLE="width:2.16333in;height:0.583333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>176,452,000 Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and resale by the selling stockholders identified in this prospectus or their donees, pledgees,
assignees, transferees, distributees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> (the &#147;selling stockholders&#148;) of up to an aggregate of 176,452,000 shares (the
&#147;Shares&#148;) of our common stock, par value $0.0001 per share (the &#147;common stock&#148;), issued by us in a private placement on December&nbsp;27, 2024 consisting of (i) 100,000,000 shares of our common stock and (ii) 76,452,000 shares of
our common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of our common stock held by certain selling stockholders (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT>
Warrants&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by
the selling stockholders of the Shares. We will, however, receive the net proceeds of any <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants exercised for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of the Shares by the selling stockholders may occur at fixed prices, at market prices prevailing at the time of sale, at prices related
to prevailing market prices or at negotiated prices. The selling stockholders may sell Shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the selling
stockholders, the purchasers of the Shares, or both. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are paying the cost of registering the shares of common stock covered by this
prospectus as well as various related expenses. The selling stockholders are responsible for all broker or similar commissions related to the offer and sale of their Shares. See the section titled &#147;Plan of Distribution&#148; on page 12 for more
information about how the selling stockholders may sell or dispose of their Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global
Market under the trading symbol &#147;RAPT.&#148; On January&nbsp;27, 2025, the last reported sale price of our common stock was $1.16 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a &#147;smaller reporting company&#148; as defined under the federal securities laws and, as such, have elected to comply with certain
reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein and may elect to comply with reduced public company reporting requirements in future filings. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the
section titled &#147;<A HREF="#tx885645_4">Risk Factors</A>&#148; on page 6 of this prospectus and any similar section contained in any amendment or supplement to this prospectus or in any filing with the Securities and Exchange Commission that is
incorporated by reference into this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission
has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is January&nbsp;27, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885645_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885645_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885645_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885645_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885645_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885645_6">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885645_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885645_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885645_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885645_10">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx885645_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885645_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and
Exchange Commission (&#147;SEC&#148;). Under this registration statement, the selling stockholders may sell from time to time in one or more offerings the common stock described in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may be supplemented from time to time by one or more prospectus supplements. Such prospectus supplement may also add, update
or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement, you must rely on the information in the prospectus supplement. You should
carefully read both this prospectus and any applicable prospectus supplement together with additional information described under the heading &#147;Where You Can Find Additional Information&#148; before deciding to invest in the Shares being
offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with information other than the information that we have provided or incorporated
by reference in this prospectus and your reliance on any unauthorized information or representation is at your own risk. This prospectus may be used only in jurisdictions where offers and sales of these securities are permitted. You should assume
that the information appearing in this prospectus is accurate only as of the date of this prospectus and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of
the time of delivery of this prospectus, or any sale of our common stock. Our business, financial condition and results of operations may have changed since those dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885645_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus or incorporated by reference in this prospectus and does not
contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of
investing in our securities discussed under the sections titled &#147;Risk Factors&#148; contained in this prospectus, the applicable prospectus supplement, if any, and any related free writing prospectus, and under similar sections in the other
documents that are incorporated by reference into this prospectus. You should also carefully read the other information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration
statement of which this prospectus is a part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for
patients living with inflammatory and immunological diseases. Our lead drug candidate, RPT904, is a half-life extended monoclonal antibody (&#147;mAb&#148;) designed to bind free human immunoglobulin E (&#147;IgE&#148;), a key driver of several
allergic diseases. We have entered an exclusive license agreement with Shanghai Jemincare Pharmaceutical Co., Ltd (&#147;Jemincare&#148;), a subsidiary of Jiangxi Jemincare Group, under which we have rights to develop and commercialize RPT904
worldwide excluding mainland China, Hong Kong, Macau and Taiwan. As consideration for the license, we paid Jemincare a $35&nbsp;million upfront license fee and could make up to $672&nbsp;million in additional payments upon the achievement of
specified milestones, as well as pay high single-digit to low double-digit royalties on future net sales. We believe RPT904 could offer patients a potentially improved therapeutic option compared to omalizumab (marketed as Xolair<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>), an <FONT STYLE="white-space:nowrap">anti-IgE</FONT> antibody approved for asthma, chronic spontaneous urticaria (&#147;CSU&#148;), chronic rhinosinusitis with nasal polyps and food allergy. In
a Phase 1 clinical study, the median half-life of RPT904 was more than two times that of omalizumab at the same dose and RPT904 showed deeper and more sustained reduction of free IgE and higher total IgE accumulation compared to omalizumab at the
same dose. We plan to pursue clinical development of RPT904 initially in food allergy and CSU. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the state of Delaware in March 2015 under the name FLX Bio, Inc. In May 2019, we changed our name to
RAPT Therapeutics, Inc. Our principal executive offices are located at 561 Eccles Avenue, South San Francisco, CA 94080. Our website address is <I>www.rapt.com</I>. Information contained on, or that can be accessed through, our website is not
incorporated by reference into this report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus includes trademarks, service marks and trade names owned by us or other
companies. All trademarks, service marks and trade names included herein are the property of their respective owners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Smaller Reporting Company Status
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). We
may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i)&nbsp;our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT>
common stock held by nonaffiliates is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter or (ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and
our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Securities Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;23, 2024, we entered into a Securities Purchase Agreement (the &#147;Purchase Agreement&#148;), pursuant to which we agreed to issue and sell 176,452,000 Shares, consisting of (i) 100,000,000 shares of our common stock (the &#147;PIPE
Shares&#148;) and (ii) 76,452,000 shares of our common stock issuable upon the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrant Shares&#148;) (such
transaction, the &#147;Private Placement&#148;). The purchase price per PIPE Share was $0.85 and the purchase price per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant was $0.8499. Our total net proceeds from the sale of securities in the
Private Placement, after deducting commissions to the placement agent and offering expenses, were approximately $143.5&nbsp;million, which does not include any proceeds that may be received upon exercise of any
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants issued in the Private Placement for cash. The closing of the Private Placement occurred on December&nbsp;27, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have an exercise price of $0.0001 per share, are exercisable immediately and
are exercisable until a <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant is exercised in full. In lieu of making the cash payment upon exercise of a <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, the holder may elect instead
to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, we may not give effect to the exercise of any such <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, and a holder will not be entitled to exercise any portion of any such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, if, upon giving effect to such exercise, the aggregate number of
shares of common stock beneficially owned by the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder&#146;s affiliates, and any other persons whose beneficial ownership of common
stock would or could be aggregated with the holder&#146;s for purposes of Section&nbsp;13(d) or Section&nbsp;16 of the Exchange Act) would exceed 4.99% or 9.99%, as applicable, of the number of shares of common stock outstanding immediately after
giving effect to such exercise, which percentage may be increased or decreased at the holder&#146;s election upon notice to us, up to 19.99%; provided that any such increase will not be effective until the 61<SUP
STYLE="font-size:75%; vertical-align:top">st</SUP> day after delivery of such notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Private Placement, we entered into a registration rights agreement (the &#147;RRA&#148;) with the selling stockholders,
pursuant to which we agreed to register for resale the PIPE Shares and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares. Under the RRA, we agreed to file a registration statement covering the resale by the selling stockholders
of the Shares no later than 30 days following the closing of the Private Placement and to use reasonable efforts to have the registration statement declared effective at the earliest possible date but no later than the earlier of (a)&nbsp;the 75th
calendar day following the initial filing date of the registration statement if the SEC notifies us that it will review the registration statement and (b)&nbsp;the fifth business day after the date the SEC notifies us that the registration statement
will not be reviewed or be subject to further review. The registration statement of which this prospectus forms a part is being filed in part to satisfy the requirements of the RRA. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock offered by the selling stockholders </P></TD>
<TD>We are registering the resale by the selling stockholders of an aggregate of 176,452,000 Shares, consisting of: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 100,000,000 PIPE Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 76,452,000 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the offering </P></TD>
<TD>Each selling stockholder will determine when and how it will sell the common stock offered in this prospectus, as described in the &#147;Plan of Distribution&#148; on page 12. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of the Shares. We will, however, receive the exercise price of $0.0001 per share of any of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants exercised for cash. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>See &#147;Risk Factors&#148; on page 6 for a discussion of factors you should carefully consider before deciding to invest in our common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market symbol </P></TD>
<TD>&#147;RAPT&#148; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885645_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents we have filed with the SEC that are incorporated by reference contain &#147;forward-looking statements&#148;
within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and Section&nbsp;21E of the Exchange Act. These statements relate to future events or to our future operating or financial performance
and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the
forward-looking statements. Forward-looking statements may include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our total addressable market, future revenue, expenses, capital requirements and our needs for
additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, cost, timing, progress and results of research and development activities, preclinical studies
and clinical trials with respect to RPT904, tivumecirnon (FLX475) and other potential future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, develop and commercialize drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance RPT904, tivumecirnon or other future drug candidates into, and successfully complete,
preclinical studies and clinical or field trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of RPT904, tivumecirnon or other future drug candidates,
and any related restrictions, limitations and/or warnings in the label of an approved drug candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and expand our drug discovery and development engine; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify drug candidates using our drug discovery and development engine; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately
under those arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain intellectual property protection for our technology and any of our drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize any of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of any of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and international jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential liability lawsuits and penalties related to our technology, our drug candidates and our current and
future relationships with third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effectively manage the growth of our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to compete effectively with existing competitors and new market entrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding uses of proceeds from capital raising transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential effects of extensive government regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volatility of the trading price of our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors.&#148;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as
&#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;will,&#148;
&#147;would,&#148; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these
assumptions, risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail many of these risks under the heading &#147;Risk Factors&#148; contained in the this prospectus, in any
applicable prospectus supplement, in any free writing prospectuses we may authorize for use in connection with a specific offering, and in our most recent Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;and</FONT> in our most
recent Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,&nbsp;as</FONT> well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety. Also,
these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements
to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus,
any applicable prospectus supplement, together with the documents we have filed with the SEC that are incorporated by reference and any free writing prospectuses that we may authorize for use in connection with a specific offering completely and
with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885645_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should consider
carefully the risks and uncertainties discussed in this section and under the sections titled Risk Factors contained in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our subsequent Quarterly Reports on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended subsequent to our filing of such Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as well as any amendments or updates to our risk factors reflected
in subsequent filings with the SEC, which are incorporated by reference into this prospectus, together with other information in this prospectus, the documents incorporated by reference, any prospectus supplement and any free writing prospectus that
we may authorize. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the
risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial condition, results of operations and cash flow could be materially and adversely affected. In that case, the
trading price of our common stock could decline and you might lose all or part of your investment. Please also read carefully the section titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our research and development and manufacturing activities may take place in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions,
such as China, through third-party CROs, collaborators or manufacturers. A significant disruption in the operation of those CROs, collaborators or manufacturers could materially adversely affect our business and results of operations.</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may contract many of our research, manufacturing and preclinical or clinical activities to third parties outside the United States,
including without limitation, in China. For example, pursuant to our License Agreement with Jemincare, a company incorporated in People&#146;s Republic of China, we expect Jemincare will provide the initial supply of drug product for certain of our
clinical trials and may act as a supplier for our future needs. Any disruption in the operations of Jemincare or other third parties or in their ability to meet our needs, whether as a result of a natural disaster, war, government regulation or
other causes, could impair our ability to operate our business on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> basis and to continue development of our programs. Furthermore, as is the case with
Jemincare, since some of these third parties are located outside the United States, we are exposed to the possibility of disruption and increased costs in the event of changes in the policies of the United States or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments, war, political unrest or unstable economic conditions in any of the countries where we conduct such activities. For example, a war or trade war could lead to tariffs, embargoes, sanctions
or other limitations on trade, such as those placed on Russia as a result of its ongoing military invasion of Ukraine, may affect our ability to source clinical trial products or other materials from affected third parties or conduct certain
research, development or manufacturing activities. In addition, in recent years, China and the United States have implemented certain increasingly protective trade measures with continuing trade tensions, including significant tariff increases,
between these countries. If any of these events were to occur it could materially and adversely affect our development timelines, business, financial condition, results of operations and prospects.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885645_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale or other disposition of the Shares offered pursuant to this prospectus. Upon any
exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants for cash, the applicable selling stockholder would pay us the exercise price set forth in the applicable <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant has an exercise price equal to $0.0001 per share, and if all 76,452,000 <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants registered hereunder are exercised on a cash basis, we will receive proceeds of approximately $7,645. We intend to use any proceeds from the exercise of any
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants for working capital and general corporate purposes. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are exercisable at any time after their original issuance on
December&nbsp;27, 2024 and will not expire until exercised in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are
exercisable on a net exercise cashless basis. If any of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are exercised on a cashless basis, we would not receive any cash payment from the applicable selling stockholder upon any such
exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will bear the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, expenses
and fees incurred in connection with the registration of shares of our common stock to be sold by the selling stockholders pursuant to this prospectus. Other than registration expenses, the selling stockholders will bear their own broker or similar
commissions payable with respect to sales of the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885645_6"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock being offered by the selling stockholders consist of the (i)&nbsp;the PIPE Shares and (ii)&nbsp;the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares. For additional information regarding the issuance of the PIPE Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in connection with the Private Placement, see the
section &#147;Prospectus Summary&#151;Recent Developments&#150;Private Placement&#148; above. We are registering the resale of the PIPE Shares issued to the selling stockholders and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant
Shares issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in order to permit such selling stockholders to offer the Shares for resale from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to our common
stock. Generally, a person &#147;beneficially owns&#148; shares of our common stock if the person has or shares with others the right to vote those shares or to dispose of them, or if the person has the right to acquire voting or disposition rights
within 60 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below lists the selling stockholders and other information regarding the beneficial ownership of the shares of
common stock by each of the selling stockholders. This information has been obtained from the selling stockholders or in Schedules 13G or 13D and other public documents filed with the SEC. The second column lists the number of shares of common stock
beneficially owned by each selling stockholder, based on its ownership of shares of common stock, PIPE Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares, as of January&nbsp;13, 2025, assuming exercise of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants held by the selling stockholders on that date, after giving effect to any limitations on exercise. The third column assumes the sale of all of the shares offered by the selling stockholders
pursuant to this prospectus. The percentage of shares beneficially owned after the offering in the fifth column is based on 132,006,828 shares of common stock outstanding as of January&nbsp;13, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the RRA, this prospectus covers the resale of the sum of (i)&nbsp;the PIPE Shares and (ii)&nbsp;the maximum
number of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants issued in the Private Placement. This maximum amount is determined as if the
outstanding <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC, subject to adjustment as provided in
the RRA and without regard to any limitations on the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. Under the terms of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, a selling stockholder may not
exercise the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to the extent such exercise would cause such selling stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock
which would exceed 4.99% or 9.99%, as applicable to each holder, of the number of shares of our common stock outstanding following such exercise (for purposes of the denominator, immediately after giving effect to the issuance of shares of common
stock to be issued upon the applicable exercise of such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant). The number of shares in the third column does not reflect this limitation. The selling stockholders may sell all, some or none of
their shares in this offering. See the section &#147;Plan of Distribution.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial Ownership<BR>Before Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B><br><B>Number of</B><br><B>Shares</B><br><B>Offered<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial&nbsp;Ownership&nbsp;After&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B><br><B>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,983,940</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,116,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foresite Capital Fund VI LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,544,914</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,352,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Medicxi IV LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,352,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.93</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,352,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with OrbiMed Advisors LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,193,277</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,644,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,880,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,880,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial Ownership<BR>Before Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B><br><B>Number of</B><br><B>Shares</B><br><B>Offered<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial&nbsp;Ownership&nbsp;After&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B><br><B>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Redmile Group, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,932,449</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,644,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,490,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RTW Investments, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TCG IV Funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,865,956</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,408,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,278,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TCG Crossover Fund II, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,193,277</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,528,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Percentage not listed if less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For calculations for the number of Shares being offered pursuant to this prospectus, we are assuming, in
accordance with the RRA, the exercise in full of all of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants without regard to any beneficial ownership limitations on exercise as described above and as set forth in the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) (a) 4,747,700 PIPE Shares and (b) 1,298,481 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrant Shares held by Biotechnology Value Fund, L.P. (&#147;BVF&#148;), (ii) (a) 3,835,620 PIPE Shares and (b) 1,049,031 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares held by Biotechnology Value Fund II, L.P. (&#147;BVF
II&#148;), (iii) (a) 477,406 PIPE Shares and (b) 130,569 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares held by Biotechnology Value Trading Fund OS LP (&#147;BVF Trading&#148;) and (iv) (a) 176,830 PIPE Shares and (b) 48,363 <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares held by MSI BVF SPV, LLC (&#147;MSI BVF&#148; and together with BVF, BVF II and BVF Trading, the &#147;BVF Entities&#148;). BVF I GP LLC, as general partner of BVF, may be deemed to
beneficially own the shares held by BVF. BVF II GP LLC, as general partner of BVF II, may be deemed to beneficially own the shares held by BVF II. BVF GP Holdings LLC, as the sole member of BVF I GP LLC and BVF II GP LLC, may be deemed to
beneficially own the shares beneficially owned by BVF and BVF II. BVF Partners OS Ltd, as general partner of BVF Trading, may be deemed to beneficially own the shares beneficially owned by BVF Trading. BVF Partners L.P., or BVF Partners, as the sole
member of BVF Partners OS Ltd. and the investment adviser of each of BVF, BVF II, BVF Trading and MSI, may be deemed to beneficially own the shares beneficially owned by BVF, BVF II, BVF Trading and MSI. BVF Inc., as general partner of BVF Partners,
and Mark N. Lampert, as officer and director of BVF Inc., may be deemed to beneficially own the shares beneficially owned by BVF Partners and has shared voting and dispositive power over such shares. Each of BVF I GP LLC, BVF II GP LLC, BVF GP
Holdings LLC, BVF Partners OS Ltd., BVF Partners, BVF Inc. and Mr.&nbsp;Lampert disclaim beneficial ownership over the shares. The principal business address of the BVF Entities is 44 Montgomery Street, 40th Floor, San Francisco, CA 94104.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 6,011,380 PIPE Shares and (ii) 7,972,560 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrant Shares. Excludes 132,060 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares issuable to Deep Track Biotechnology Master Fund, Ltd. in connection with the Private Placement, which
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are not exercisable within 60 days of January&nbsp;13, 2025 by virtue of the beneficial ownership limitations described above. Deep Track Capital GP, LLC (the &#147;Deep Track GP&#148;) is
the general partner of Deep Track Capital, LP (&#147;Deep Track LP&#148;). Deep Track LP is the investment manager for Deep Track Biotech. David Kroin is the managing member of Deep Track GP. The principal business address for Deep Track Biotech is
200 Greenwich Avenue, 3rd Floor, Greenwich, CT 06830. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 12,500,000 PIPE Shares and (ii) 44,914 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant
Shares. Excludes 9,807,086 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares issuable to Foresite Capital Fund VI LP (&#147;Foresite Capital&#148;) in connection with the Private Placement, which
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are not exercisable within 60 days of January&nbsp;13, 2025 by virtue of the beneficial ownership limitations described above. Foresite Capital Management VI, LLC (&#147;FCM VI&#148;), the
general partner of Foresite Capital, may be deemed to have sole power to vote these shares, and James Tananbaum, the managing member of FCM VI, may be deemed to have sole power to vote these shares. The principal business address of Foresite Capital
is 900 Larkspur Landing Circle, Suite 150, Larkspur, CA 94939. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 21,977,977 PIPE Shares held by Medicxi IV LP (&#147;Medicxi IV&#148;) and (ii) 374,023 PIPE Shares
held by Medicxi <FONT STYLE="white-space:nowrap">Co-Invest</FONT> IV LP (&#147;Medicxi <FONT STYLE="white-space:nowrap">Co-Invest&#148;</FONT> and together with Medicxi IV, the &#147;Medicxi
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Entities&#148;). Medicxi IV GP, as the general partner of each of the Medicxi Entities, and Medicxi Ventures Management (Jersey) Limited, as the appointed manager of each of the Medicxi Entities,
may be deemed to beneficially own the shares beneficially owned by the Medicxi Entities. The principal business address of the Medicxi Entities is 44 Esplanade, St. Helier, Jersey, Channel Islands, JE4 9WG. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) (a) 6,567,630 PIPE Shares and (b) 29,009 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrant Shares held by OrbiMed Genesis Master Fund, L.P. (&#147;OrbiMed Genesis&#148;) and (ii) (a) 6,567,630 PIPE Shares and (b) 29,008 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares held by OrbiMed Private Investments IX, LP
(&#147;OPI IX&#148; and together with OrbiMed Genesis, the &#147;OrbiMed Entities&#148;). Excludes 4,450,723 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares issuable to the OrbiMed Entities in connection with the Private Placement,
which <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are not exercisable within 60 days of January&nbsp;13, 2025 by virtue of the beneficial ownership limitations described above. OrbiMed Genesis GP LLC (&#147;Genesis GP&#148;) is the
general partner of OrbiMed Genesis, and OrbiMed Advisors LLC (&#147;OrbiMed Advisors&#148;) is the managing member of Genesis GP. OrbiMed Advisors exercises investment and voting power through a management committee comprising Carl L. Gordon, Sven
H. Borho and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis, except to the extent of his pecuniary interest therein if any. OrbiMed Capital GP IX LLC (&#147;GP IX&#148;) is the general partner of
OPI IX, and OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI IX and as a result, may be deemed to
have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprising Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the
shares held by OPI IX. The principal business address of the OrbiMed Entities is 601 Lexington Avenue, 54th Floor, New York, NY 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 5,880,000 PIPE Shares. Joseph Edelman is the managing member of the Perceptive Life Sciences Master
Fund Ltd. and in his capacity as Chief Executive Officer and Portfolio Manager has sole voting power over the securities. The principal business address of Perceptive Life Sciences Master Fund, Ltd. is c/o Perceptive Advisors LLC, 51 Astor Place,
10th Floor, New York, NY 10003. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) (a) 102,191 PIPE Shares and (b) 7,457,132 shares of common stock issuable upon the exercise of
outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (including 3,457,132 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares) held by Redmile Biopharma Investments III, L.P. (&#147;Redmile Biopharma&#148;), (ii)
4,042,190 PIPE Shares held by Redmile Strategic Long Only Trading Sub, Ltd. (&#147;Redmile Long&#148;), (iii) 1,840,163 PIPE Shares held by Redmile Strategic Trading Sub, Ltd. (&#147;Redmile Trading&#148; and together with Redmile Biopharma and
Redmile Long, the &#147;Redmile Funds&#148;) and (iv) 490,773 shares of common stock held by certain funds managed by Redmile Group, LLC (&#147;Redmile Group&#148;). Excludes 8,202,324 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant
Shares issuable to Redmile Biopharma in connection with the Private Placement, which <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are not exercisable within 60 days of January&nbsp;13, 2025 by virtue of the beneficial ownership
limitations described above. Redmile Group is the investment manager to each of the entities listed in (i)&nbsp;to (iv) above and, in such capacity, exercises voting and investment power over all of the securities held by such entities and may be
deemed to be the beneficial owner of these securities. Jeremy C. Green serves as the principal of Redmile Group and also may be deemed to be the beneficial owner of these securities. Redmile Group and Mr.&nbsp;Green each disclaim beneficial
ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. The address of the Redmile Funds is c/o Redmile Group, LLC, One Letterman Drive, Building D, Suite
<FONT STYLE="white-space:nowrap">D3-300,</FONT> San Francisco, California 94129. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 11,764,000 PIPE Shares held in the aggregate by RTW Master Fund, Ltd., RTW Innovation Master Fund,
Ltd. and RTW Biotech Opportunities Ltd (the &#147;RTW Funds&#148;). RTW Investments, LP (&#147;RTW&#148;), in its capacity as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held
by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr.&nbsp;Wong
disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The address and principal office of RTW Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of Dr.&nbsp;Wong and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 1,236,261 shares of common stock held by The Column Group IV, LP (&#147;TCG IV LP&#148;), (ii)
42,189 shares of common stock held by The Column Group <FONT STYLE="white-space:nowrap">IV-A,</FONT> LP (&#147;TCG <FONT STYLE="white-space:nowrap">IV-A</FONT> LP&#148; and together with TCG IV LP, the &#147;TCG IV Funds&#148;) and (iii) 5,587,506 <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares issuable to upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants held by the TCG IV Funds. Excludes 23,820,494 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrant Shares issuable upon exercise of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants held by the TCG IV Funds, which <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are not exercisable within 60 days of January 13, 2025
by virtue of the beneficial ownership limitations described above. The Column Group IV GP, LP (&#147;TCG IV GP LP&#148;) is the general partner of TCG IV LP and TCG <FONT STYLE="white-space:nowrap">IV-A</FONT> LP and may be deemed to have voting,
investment and dispositive power with respect to these securities. TCG IV GP LLC (&#147;TCG IV LLC&#148;) is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and TCG <FONT STYLE="white-space:nowrap">IV-A</FONT> LP
and may be deemed to have voting, investment and dispositive power with respect to these securities. David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the &#147;TGC IV Managing Members&#148;) are the managing members of TCG IV LLC. The
TCG IV Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to
the extent of their respective pecuniary interest in such securities. The principal business address for the TCG IV Funds is 1 Letterman Drive, Suite <FONT STYLE="white-space:nowrap">DM-900,</FONT> San Francisco, CA 94129. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (i) 13,135,260 PIPE Shares and (ii) 58,017 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant
Shares held by TCG Crossover Fund II, LP (&#147;TCGX&#148;). Excludes 10,334,723 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares issuable upon exercise of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants held by TCGX,
which <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are not exercisable within 60 days of January&nbsp;13, 2025 by virtue of the beneficial ownership limitations described above. TCG Crossover GP II, LLC (&#147;TCGX GP&#148;) is the
general partner of TCGX and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCGX GP and may be deemed to share voting, investment and dispositive power with
respect to these securities. TCGX GP and Chen Yu disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. The principal business address for TCGX is c/o TCG Crossover
Management, LLC, 705 High Street, Palo Alto, California 94301. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Selling Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brian Wong, M.D., Ph.D., who is a member of our Board of Directors, holds the title of Venture Partner with The Column Group. Dr.&nbsp;Wong
does not have any voting, investment or dispositive power with respect to the securities held by the TCG IV Funds or their affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885645_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders, which as used herein includes donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution
or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or
in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may use any one or more of the following methods when disposing of the Shares or interests therein: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distributions to members, partners, stockholders or other equityholders of the selling stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales and settlement of short sales entered into after the effective date of the registration statement of
which this prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by
them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act, amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also
may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling stockholders for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these
securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other
financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial
institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling stockholders from the sale of the common stock offered
by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any
proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants by payment of cash, however, we
will receive the exercise price of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders also may
resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the
registration requirements under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any underwriters, broker-dealers or agents that
participate in the sale of the common stock or interests therein may be &#147;underwriters&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act (it being understood that the selling stockholders shall not be deemed to be
underwriters solely as a result of their participation in this offering). Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling
stockholders who are &#147;underwriters&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and
public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective
amendment to the registration statement that includes this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if
applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption
from registration or qualification requirements is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the selling stockholders that the
anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this
prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any
broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities
laws, relating to the registration of the shares offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the selling stockholders to use
commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of: (i)&nbsp;the date on which the selling stockholders shall
have resold or otherwise disposed of all the shares covered by this prospectus and (ii)&nbsp;the date on which the shares covered by this prospectus no longer constitute &#147;Registrable Securities&#148; as such term is defined in the RRA, such
that they may be resold by the selling stockholders without registration and without regard to any volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations and without current public
information pursuant to Rule 144 under the Securities Act or any other rule of similar effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885645_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP, Chicago, Illinois, will pass upon the validity of the securities offered by this prospectus and any supplement thereto. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885645_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of RAPT Therapeutics, Inc. appearing in RAPT Therapeutics, Inc.&#146;s Annual Report (Form <FONT
STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2023 have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as forth in their report thereon included therein, and incorporated
herein by reference. Such financial statements are incorporated herein by reference in reliance upon the report of Ernst&nbsp;&amp; Young LLP pertaining to such financial statements given on the authority of such firm as experts in accounting and
auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885645_10"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the
Securities Act and does not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may
not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other
document. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over
the Internet at the SEC&#146;s website at <I>www.sec.gov</I>. In addition, we maintain a website that contains information about us at <I>www.rapt.com</I>. Information contained on or accessible through our website is not a part of this prospectus
and is not incorporated by reference herein, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx885645_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we
filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the
registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-38997):</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000095017024027594/rapt-20231231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2023, filed with the SEC on March&nbsp;7, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000119312524088453/d769371ddef14a.htm">Schedule
 14A</A>, filed with the SEC on April&nbsp;5, 2024 (excluding those portions that are not incorporated by reference into our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000095017024056302/rapt-20240331.htm">March
<U></U>&nbsp;31, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000095017024093354/rapt-20240630.htm">June<U></U>&nbsp;
30, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000095017024124624/rapt-20240930.htm">September<U></U>&nbsp;30, 2024</A>, filed with the SEC on May&nbsp;9, 2024, August&nbsp;8, 2024 and November&nbsp;12, 2024, respectively;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000095017024017155/rapt-20240220.htm">February
<U></U>&nbsp;20, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000095017024064001/rapt-20240522.htm">May<U></U>&nbsp;
23, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000095017024084991/rapt-20240716.htm">July<U></U>&nbsp;
19, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000095017024127689/rapt-20241112.htm">November<U></U>&nbsp;
15, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000119312524283668/d926285d8k.htm">December<U></U>&nbsp;
23, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000095017024139667/rapt-20241222.htm">December<U></U>&nbsp;
23, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000095017025002193/rapt-20250103.htm">January<U></U>&nbsp;6, 2025</A>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock set forth in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000119312519199060/d779692d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on July&nbsp;
22, 2019, including any amendment or report filed for the purpose of updating such description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-ex42_1343.htm">Exhibit 4.2</A> to our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the statements
in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information that we have &#147;furnished&#148; to the SEC pursuant to the Exchange Act shall be incorporated by reference into this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or
Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made
after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the termination of the offering
of the securities made by this prospectus and will become a part of this prospectus from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any
statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that
statements in the later filed document modify or replace such earlier statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any
beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits
that are specifically incorporated by reference into such documents. You should direct any requests for documents to RAPT Therapeutics, Inc., Attn: Chief Financial Officer, 561 Eccles Avenue, South San Francisco, California 94080; telephone: (650) <FONT
STYLE="white-space:nowrap">489-9000.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:25pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g885645g20l00.jpg" ALT="LOGO" STYLE="width:3.19667in;height:0.85in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>176,452,000 Shares of Common Stock </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>January&nbsp;27, 2025 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g885645g03l00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g885645g03l00.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[18<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &$< 5H  QLE1QP"   "   < E  "')R-#$T-S W' (% $!-:6-R;W-O
M9G0@5V]R9" M(%)!4%0@+2 R,#(T(%!)4$4@+2!297-A;&4@4RTS(%]#;V]L
M97D@,2XQ-RXR-5\@ #A"24T$)0      $#^[[$ME40\1W3X3F,F%SQHX0DE-
M!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ $L     0 ! 2P    !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@              KP   HD    & &< ,  S
M &P ,  P     0                         !              *)
MKP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
MKP    !29VAT;&]N9P   HD    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   *\     4F=H=&QO;F<
M  *)     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MAFT &/SG>HANRKP7%KG$^J:V-+/8?=L:TV_]^W?3_P Q1M_I#OZ']+\_Z?\
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M &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M(  R #  ,@ T     0 X0DE-!"(      49-30 J    "  ( 1(  P    $
M 0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M "    !^ 3(  @   !0   "> 3L  @    D   "RAVD !     $   "\
MZ    2P    !   !+     %!9&]B92!0:&]T;W-H;W @,C4N,3(@*%=I;F1O
M=W,I #(P,C4Z,#$Z,3@@,#4Z,C Z,S< <G(T,30W,#<    #H $  P    '_
M_P  H ( !     $   *)H , !     $   "O          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
M 0   48" @ $     0              2     $   !(     3A"24T#_0
M    "           _^$!3D5X:68  $U- "H    (  @!$@ #     0 !   !
M&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "    (
M 'X!,@ "    %    )X!.P "    "0   +*':0 $     0   +P   #H   !
M+     $   $L     4%D;V)E(%!H;W1O<VAO<" R-2XQ,B H5VEN9&]W<RD
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M2*>#<,'(R#NZURH)LHU4+]9A2U#O][2-#7?Q-Z"IVJ6L%J>0B(L&0B(@"(B
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M#:VT;:&F//<X^^O9WE37/CLO!U30LFA?'*T.8\8<#P(5&:YT?/8ZITU,U\M
M\Y:\#Y&_@5?"ZIX8ZB%T4S&R1N&"UPR"HW=I&YCA[-<,GT_J$[*>5NGRC5U<
M*Y+_ +,Z.K>Z2URBD>3DL<"YOY=2B<^S2^1N/@Q!(T<"V3'Z%<_4L*]-XTY^
M#KZ/5[2LLZ\?.Q!UGM*_\D_H"S=-LSO<CP)? 1-Z27YQ^04WTIH"FM&9*V45
M4IZ ,-5;Z;<5XN*CCY*[KJMK3@TIY?MN8_3%@DKY1-4-<RF:<[Q\OS*QF-:Q
MH:T  #  1C&L8&L :T;@ %]+H.GV$+*GICNWRSC[N[G<SU2X[((B+?-0(B(
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M\PWV%9CR8?!K^LEIOZ>H/QF^U8U9+3?T]0?C-]JN*T;9C@B#@BH+0B(@"(B
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M0FG(M.6*&F:T>,. =,\=+O\ "S)X1B*R2"&-D,38XFAK&C  ' +[1%26A$1
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MH7WIVY&XT(,FZH9Y,C3U]:HM93MY_9JKSW3\^5^'Z%E91JQ]:"QY7Z&4>?\
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&UCA+!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g885645g20l00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g885645g20l00.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1:\4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ $L     0 ! 2P    !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@              _P   [\    & &< ,@ P
M &P ,  P     0                         !              ._
M_P                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M_P    !29VAT;&]N9P   [\    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   /\     4F=H=&QO;F<
M  ._     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M'J.!C;]H>?\ IKI?K9UW]D]/VTN S,F64_R0/YW(/_%-/M_X7TTB-5 Z./\
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M;'%H=L.QUEFW;OWO;_84OJ]UO+P^H48UECK<7(<VIU;W%VUSCMK?67>YGO\
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M      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4
M   !    =@$H  ,    !  (   $Q  (    @    ?@$R  (    4    G@$[
M  (    )    LH=I  0    !    O    .@   $L     0   2P    !061O
M8F4@4&AO=&]S:&]P(#(U+C$R("A7:6YD;W=S*0 R,#(U.C Q.C$X(# U.C(T
M.C(R ')R-#$T-S W     Z !  ,    !__\  * "  0    !   #OZ #  0
M   !    _P         & 0,  P    $ !@   1H !0    $   $V 1L !0
M  $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M     $@    !    2     $X0DE- _T       @          /_A 4Y%>&EF
M  !-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $
M  !V 2@  P    $  @   3$  @   "    !^ 3(  @   !0   "> 3L  @
M  D   "RAVD !     $   "\    Z    2P    !   !+     %!9&]B92!0
M:&]T;W-H;W @,C4N,3(@*%=I;F1O=W,I #(P,C4Z,#$Z,3@@,#4Z,C0Z,C(
M<G(T,30W,#<    #H $  P    '__P  H ( !     $   ._H , !     $
M  #_          8! P #     0 &   !&@ %     0   38!&P %     0
M 3X!*  #     0 "   " 0 $     0   48" @ $     0
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M-E-587%RL=$T0H'!(R0S4J%B8W.30R5D@O!TLN'_Q  < 0$  @,! 0$
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MTBJ%XK)SK(NHG%/40U,224\C)(UUHYJYHI%K!)/)]0 8,@
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M8ZBN$4K=B.3/X%L0R)+$U[5S14S/<<$O7<T=$_>B>5XG:JA4U1V9W !VCF@
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M'JV2-R*BH;-8%Q#%B&R13M=_&8B-E;N4JG'J60?0D8 ($P         ,DW
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M&].$U4YT/J5/H9Q9W>G2SULGCQI_"<Y=J;BV$*&L%R>0 #!D
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M^7D<KHU3=N-@S#8HL4%]MSX)DR>B*K'IM12N_M?6(>SNMB[A5_ZG5]KW7O\
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MS.7<9;P87,L/0_A1+=0=\ZMJ<9G3Q$7\K2RSI$QL4;61HB-:F2(AW*6\EJ6
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MOIE6_%/JI$"^.Q4P6=H,\^S?+^Q6)9V@SS[-\O[&);!;E[@ I+0
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MJKFC$R3>I\TU+GM7>IR#V-EPVA9KV%S[WN?+>*\>O.*2S6E[/<M@ #?.,
M<IM0OK1/2]QPK#*O_ES7_)1MNIGU=9%!&U7.D>C41/B;+6"A;;K334K-C&(:
M5[+$5$[7!*3E5E4Z)&10! <P]0      4IIX_'TOR_<J4MK3Q^/I?E^Y4I=#
M8JEN#.X(])*+YS!&=P1Z247SF7L11M-%_3;\$.QUB_IM^"'8H+P
M   =)8VRQNCD3A,<F2H=P :Z:4,).L-T=44[%XG.Y7-7F:N>P@IMCB2S4]\M
M4]'4L:[AM7@JJ9\%>936+$EGGLEUGHZAKD5CLD54\I-Z%L)9*I+!BS[T-5)1
MU4<\#N#)&Y'-5-Y\ 3(FS>C[$T>(;/&YSDXW&F4C?W)-/*R")TDKD:QJ9JJ\
MQJ]@K$,V'KQ'4QN7N2^+(W/:W,LC2GC>&2T1T-LF1SJAB.D<QWDIN*G'F6*7
M+F0C27B=]_O+DC=_*P*K8TZTS(<<JN:YJ<%J6"O<&8PI99[Y>8*2!JJCG)PE
MW-YS$QL61Z-:F:JN2(;#:*,*I9;0E54M_FZA$=K36Q-Q&3PC,5EDOLEMAM-L
M@HZ9N4<3<D/< 4EP                  ,)B^Q0W^S34DJ>/DJL=N<9L#8&
MHUUH)K;734U0Q6R1NR5%/&7AIEPKQJF6[T<:++&B)*C4VIO*05,E5%+XO**6
ML'!86B7%:V>Z-HZI^5'.N2JOY5*].T;E8Y'-7)4YT#60G@V-TN.1V!ZES5S1
M58J+^IKB[RE^)9\N*FWC1G4T=7)_-TZL:BN=K>F:%8+M4Q!81F3R<':/RT.I
MVC\M"1$VIP3Z*6O_ (&F:,+@GT4M?_ TS10]RY;  &#(
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MWYG,5$0V#BL5KB7..A@:ON:9"*-L3.#&U&MW(8E??"B5/@7/[2?D5GA;1G'
MYL]XD21R+FD34U?J6334\5-"V*GC;'&FQK4R0^P-.I5E4>9,[%O:4K98IH(
M"LV0        "!Z0\%38GJ(9(9VQ\!,M:$/\#U7TUG478"2DT1<4RD_ ]5]-
M9U'OL.BRIMUT@JGU;'-C=GED6Z!K8THX8F343<AR 1)
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M ")D
M
M
M
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M%U"G=0E]I-2CX8975G0E'V(M/Q/2 #>-8
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MLJ%S%>ULUL8J4*4Z;J47MNF2T '5-$
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1E'9+_+,SJTJ=-TZ7/.[9_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
